785 related items for PubMed ID: 17710401
1. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C.
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[Abstract] [Full Text] [Related]
2. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, Park CJ, Huh J, Suh C.
Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990
[Abstract] [Full Text] [Related]
3. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, del Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, San Miguel JF.
Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
[Abstract] [Full Text] [Related]
4. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH, Schwartzberg L, Li W, Hazelton B, West W.
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[Abstract] [Full Text] [Related]
5. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD.
Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
[Abstract] [Full Text] [Related]
6. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[Abstract] [Full Text] [Related]
7. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E.
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[Abstract] [Full Text] [Related]
8. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
Wildes TM, Augustin KM, Sempek D, Zhang QJ, Vij R, Dipersio JF, Devine SM.
Biol Blood Marrow Transplant; 2008 Jul; 14(7):840-6. PubMed ID: 18541205
[Abstract] [Full Text] [Related]
9. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Liu HW, Seftel MD, Rubinger M, Szwajcer D, Demers A, Nugent Z, Schroeder G, Butler JB, Cooke A.
Int J Radiat Oncol Biol Phys; 2010 Oct 01; 78(2):513-20. PubMed ID: 20137862
[Abstract] [Full Text] [Related]
10. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP, Roitman D, Miller KB, Morelli J, Stadtmauer E, Pecora AL, Cassileth P, Fernandez H, Cooper BW, Kutteh L, Lazarus HM.
Biol Blood Marrow Transplant; 1997 Oct 01; 3(4):210-6. PubMed ID: 9360783
[Abstract] [Full Text] [Related]
11. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Jantunen E, Mahlamäki E, Nousiainen T.
Bone Marrow Transplant; 2000 Oct 01; 26(7):737-41. PubMed ID: 11042654
[Abstract] [Full Text] [Related]
12. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I.
Bone Marrow Transplant; 1995 Apr 01; 15(4):549-55. PubMed ID: 7655380
[Abstract] [Full Text] [Related]
13. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
Seropian S, Nadkarni R, Jillella AP, Salloum E, Burtness B, Hu GL, Zelterman D, Cooper DL.
Bone Marrow Transplant; 1999 Mar 01; 23(6):599-605. PubMed ID: 10217191
[Abstract] [Full Text] [Related]
14. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.
Lancet JE, Rapoport AP, Brasacchio R, Eberly S, Raubertas RF, Linder T, Muhs A, Duerst RE, Abboud CN, Packman CH, DiPersio JF, Constine LS, Rowe JM, Liesveld JL.
Bone Marrow Transplant; 1998 Aug 01; 22(3):265-71. PubMed ID: 9720740
[Abstract] [Full Text] [Related]
15. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Jantunen E, Kuittinen T, Nousiainen T.
Leuk Lymphoma; 2003 Jul 01; 44(7):1151-8. PubMed ID: 12916867
[Abstract] [Full Text] [Related]
16. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Leger C, Sabloff M, McDiarmid S, Bence-Bruckler I, Atkins H, Bredeson C, Zhang H, Huebsch L.
Ann Hematol; 2006 Oct 01; 85(10):723-9. PubMed ID: 16832675
[Abstract] [Full Text] [Related]
17. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
Ann Hematol; 2002 Feb 01; 81(2):96-102. PubMed ID: 11907790
[Abstract] [Full Text] [Related]
18. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A.
Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):208-18. PubMed ID: 15093918
[Abstract] [Full Text] [Related]
19. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Brice P, Marolleau JP, Dombret H, Lepage E, Baruchel A, Adam M, Miclea JM, Sitthy X, Gisselbrecht C.
Bone Marrow Transplant; 1992 May 01; 9(5):337-42. PubMed ID: 1352162
[Abstract] [Full Text] [Related]
20. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci ML, Bibi Triki T, Hennequin C, Fermé C, Gisselbrecht C.
Bone Marrow Transplant; 1999 Oct 01; 24(7):747-55. PubMed ID: 10516678
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
